NovaBridge Biosciences (NBP) Common Equity (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Common Equity for 8 consecutive years, with $230.9 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity rose 14.8% year-over-year to $230.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $230.9 million (up 14.8% YoY) and the FY2025 annual result came in at $230.9 million, up 14.8% from the prior year.
• Common Equity retreated to $230.9 million in Q4 2025 per NBP's latest filing, from $258.9 million in the prior quarter.
• Over the last five years, Common Equity for NBP reached as high as $713.2 billion in Q4 2021 and fell as low as $196.7 million in Q2 2025.
• A 5-year average of $55.2 billion and a median of $238.6 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 83890.13% — and 2022, when it plunged 99.94%.
• Year by year, Common Equity stood at $713.2 billion in 2021, then tumbled by 99.94% to $409.1 million in 2022, then slumped by 41.68% to $238.6 million in 2023, then slipped by 15.7% to $201.2 million in 2024, then rose by 14.8% to $230.9 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $230.9 million, $258.9 million, and $196.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.